Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin

Executive Summary

New Phase III data for Arena Pharmaceuticals' novel obesity compound lorcaserin have disappointed the market once again, even though the company is arguing that technically speaking, they will do the trick in satisfying guidelines for FDA approval

You may also be interested in...



Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use

 

Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use

 

Obesity Drugs Face Tough Road To Approval Amid Fears Of Widespread Use

A matter of weeks away from the advisory committee review of the novel obesity drug lorcaserin, Arena's stock is flying high, yet the road to FDA approval, not to mention the daunting market, for obesity drugs looks more uncertain than ever

Related Content

Topics

UsernamePublicRestriction

Register

PS051512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel